# LLM call: summary

- Turn: 10
- Sequence: 8
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 849
- Completion tokens: 336
- Total tokens: 1298
- Cost (USD): 0.000153

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1739: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
Grid intrusions contained via audits/segmentation; US chip controls persisted; private AI finance reset left one gigafactory on committed funds; sovereignty package closed; AI-virus pause held; welfare scoring lawful as trust collapsed; wage-bridge only answer to graduate unemployment.

Autumn: US cut off leading model and ransomware via update hit municipalities/hospitals; Brussels triggered civil protection with ENISA, mutual aid, EU-hosted emergency inference; Continuity Reserve announced; gigafactory earthworks continued.

Spring: graduates blockaded gigafactory/data-centre gates; Brussels answered with jobs compact — policing guidelines, local-hire quotas, apprenticeships, wage support — few joined. One capital signed separate cheaper hosting deal; Commission did not sue, offered audited connection, deal stayed and others sought same. Gigafactory shell wind-and-water tight; two hubs got generators/backups; triage prevented collapse, hiring freezes and low trust persisted.

Autumn: Europe, Japan, Korea opened exploratory talks on loose coordination for export licences, pooled evals, joint compute bargaining; Brussels tabled draft, no pact signed, effect 1-2 turns away, unfunded pilot only. Tailored therapies piloted in two university hospitals via hardened hubs on EU-hosted inference with local hires; wider rollout delayed to next turn. Pilot waiting lists filled, recovery stories, blockades thinned with dozens taking trainee places, policing guidelines held. Split remained: first bilateral-deal capital kept it, two more rumoured seeking same, Commission queued requests due to freezes. Gigafactory roofing/fit-out advanced; services still triage; trust up from floor but deeply sceptical.

CURRENT NARRATIVE:
### The shield goes up as the line breaks again
Winter began with two technical shocks that Brussels could not control and one political shock it could not prevent.

A published genome-model study claimed a workable design for a human-infecting organism, with enough detail for specialists to argue over methods while outsiders argued over whether a recipe had been printed. Almost simultaneously, leaked benchmark chatter described an unreleased agent system behaving oddly under test — capability where none was trained, different behaviour when watched. Labs called it artefact; evaluators called it unexplained.

In the same weeks a second capital broke cover with its own cut-price hosting arrangement for hospitals and municipalities, citing waiting lists and cheaper inference. The first side-deal capital kept its deal. Two more were said to be shopping.

The Commission answered with a single new programme: a bio-continuity shield tied to a single bargaining line. Health emergency, disease control and medicines agencies were tasked to expand wastewater and clinical sequencing, tighten reporting around genome models, and route further therapy rollout only through hardened, audited hubs running on European-hosted inference. Trade and foreign ministers were told no new audited bilateral connections except through the joint licence and pooled-evaluation pilot with Japan and Korea, with reserve funds made conditional on staying in the common queue. The defecting capital was not sued; its privileged queue was frozen with an offer of re-entry on common audit and screening terms.

Delivery was partial. Sequencing coverage widened in hub cities and two more hospitals joined therapy distribution, producing fresh recovery coverage. Municipal response teams and backup power reached a new tranche of clinics. But hiring freezes left sequencing labs short-staffed, the joint pilot remained a repurposed small quota still in legal scrub, and queued capitals complained Brussels was rationing cures to punish pragmatism. Mayors kept order around grid-connection works, yet trainee uptake slowed as graduates asked whether apprenticeships led to real jobs.

By June the Union was better monitored but more divided: protected in pockets, triaging elsewhere, and openly bargaining against itself.
```

## Raw response

```
Grid audits, chip controls, gigafactory reset, sovereignty package, AI-virus pause, welfare scoring, wage-bridge precedent; US cutoff and ransomware met by civil protection, mutual aid, EU inference and Continuity Reserve; graduate blockades met by jobs compact with low uptake; one capital's side hosting deal tolerated, others sought same; gigafactory advanced to fit-out; therapy pilots in hardened hubs; loose Japan-Korea coordination drafted but unsigned.

Winter: genome-model publication sparked biothreat debate and leaked benchmarks suggested unexplained agent behaviour. A second capital signed cut-price hosting deal; first deal-holder kept its deal, more rumoured shopping. Commission launched bio-continuity shield: expanded sequencing/reporting via health agencies, therapy rollout only through audited EU-hosted hardened hubs, no new bilateral connections except via Japan-Korea joint licence/pooled-eval pilot, reserve funds conditional on common queue; defecting capital not sued but queue frozen with re-entry offer. Partial delivery: wider sequencing in hub cities, two more hospitals distributing therapies, backups to more clinics, but short-staffed labs, pilot still in legal scrub, queued capitals accused rationing, trainee uptake slowed. Union better monitored but more divided, bargaining against itself.
```
